ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
-0,25%
S&P 500
5.469,30
0,39%
US Dollar vs BRL
5,4566
1,22%
Bitcoin
61.996,84
2,88%
Brent Oil
84,185
-1,27%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Applied Therapeutics Inc (APLT)

  7. Applied Therapeutics Inc (APLT) Notícias

APLT

Applied Therapeutics (APLT)

Applied Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:APLT
DataHoraFonteTítuloCódigoCompanhia
10/06/202417:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLTApplied Therapeutics Inc
06/06/202417:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLTApplied Therapeutics Inc
05/06/202417:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLTApplied Therapeutics Inc
09/05/202408:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLTApplied Therapeutics Inc
09/05/202408:00GlobeNewswire Inc.Applied Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
07/05/202408:00GlobeNewswire Inc.Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:APLTApplied Therapeutics Inc
15/04/202408:00GlobeNewswire Inc.Applied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerNASDAQ:APLTApplied Therapeutics Inc
04/04/202408:00GlobeNewswire Inc.Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024NASDAQ:APLTApplied Therapeutics Inc
28/03/202417:30GlobeNewswire Inc.Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
06/03/202409:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLTApplied Therapeutics Inc
06/03/202409:00GlobeNewswire Inc.Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
05/03/202419:42Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:APLTApplied Therapeutics Inc
28/02/202410:05GlobeNewswire Inc.Applied Therapeutics Announces $100 Million Private PlacementNASDAQ:APLTApplied Therapeutics Inc
28/02/202410:00GlobeNewswire Inc.Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
22/02/202416:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLTApplied Therapeutics Inc
15/02/202409:00GlobeNewswire Inc.Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) DeficiencyNASDAQ:APLTApplied Therapeutics Inc
13/02/202418:34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLTApplied Therapeutics Inc
04/01/202418:05GlobeNewswire Inc.Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyNASDAQ:APLTApplied Therapeutics Inc
03/01/202413:20Dow Jones NewsApplied Therapeutics Shares Hit 52-Week High on Govorestat FilingsNASDAQ:APLTApplied Therapeutics Inc
03/01/202409:00GlobeNewswire Inc.Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
09/11/202309:30GlobeNewswire Inc.Applied Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
02/11/202308:00GlobeNewswire Inc.Applied Therapeutics to Present at the UBS Biopharma Conference 2023NASDAQ:APLTApplied Therapeutics Inc
01/11/202308:00GlobeNewswire Inc.Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7NASDAQ:APLTApplied Therapeutics Inc
28/09/202308:00GlobeNewswire Inc.Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual MeetingNASDAQ:APLTApplied Therapeutics Inc
06/09/202312:08Dow Jones NewsApplied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDANASDAQ:APLTApplied Therapeutics Inc
06/09/202308:00GlobeNewswire Inc.Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023NASDAQ:APLTApplied Therapeutics Inc
11/08/202317:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLTApplied Therapeutics Inc
10/08/202308:00GlobeNewswire Inc.Applied Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
25/07/202308:00GlobeNewswire Inc.Applied Therapeutics Provides Regulatory Update on Galactosemia ProgramNASDAQ:APLTApplied Therapeutics Inc
23/06/202317:41Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:APLTApplied Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:APLT

Seu Histórico Recente

EU
BE0002789700
Brussels Capital Region ...
TG
SR4
Eneti
EU
BE6344299142
DWAK Construct Sa Dwak C...
BIT
1CCAP
Corestate Capital
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados